Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings

Overview of attention for article published in Journal of Patient-Reported Outcomes, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#7 of 623)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 6 news outlets

twitter: 2 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 68 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer

Article in Scientific Reports (February 2024)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Article in Cost Effectiveness and Resource Allocation (November 2023)

Comparative overall survival of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer

Preprint in Research Square (August 2023)